These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37315200)

  • 1. Vogt-Koyanagi-Harada-like Syndrome Induced by Checkpoint Inhibitor Cemiplimab.
    Huang Y; Khan F; Saraiya NV; Punjabi OS; Gulati V; Erickson AR; Yeh S
    J Immunother; 2023 Oct; 46(8):295-298. PubMed ID: 37315200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib/trametinib therapy for advanced melanoma.
    Brambati M; Giuffrè C; Marchese A; Bandello F; Modorati GM; Miserocchi E
    Eur J Ophthalmol; 2022 Jan; 32(1):NP109-NP113. PubMed ID: 32998540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Steroid-Sparing Effect of Adalimumab in the Treatment for the Recurrent Phase of Vogt-Koyanagi-Harada Disease.
    Shinagawa M; Namba K; Mizuuchi K; Iwata D; Hase K; Suzuki K; Hirooka K; Kitaichi N; Hiraoka M; Ishida S
    Ocul Immunol Inflamm; 2023 Apr; 31(3):501-505. PubMed ID: 35212595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multimodal Imaging Approach in a Patient with Vogt-Koyanagi-Harada-like Syndrome Due to Dabrafenib and Trametinib Use for Cutaneous Melanoma.
    Bellanca RF; Pinna A; Catania G; Belcastro E; Angi M; D'Amico Ricci G
    Ocul Immunol Inflamm; 2023 Feb; 31(2):402-406. PubMed ID: 35113757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case with metastatic cutaneous malignant melanoma that developed Vogt-Koyanagi-Harada-like uveitis following pembrolizumab treatment.
    Enomoto H; Kato K; Sugawara A; Itabashi M; Kondo M
    Doc Ophthalmol; 2021 Jun; 142(3):353-360. PubMed ID: 33392895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Adalimumab Therapy for the Treatment of Non-infectious Uveitis: Efficacy comparison among Uveitis Aetiologies.
    Hiyama T; Harada Y; Kiuchi Y
    Ocul Immunol Inflamm; 2022 May; 30(4):951-958. PubMed ID: 33560160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vogt-Koyanagi-Harada syndrome. A case report.
    Iversen TH; Sverrisson T
    Acta Ophthalmol (Copenh); 1986 Apr; 64(2):235-8. PubMed ID: 3727967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic corticosteroid treatment in Vogt-Koyanagi-Harada disease.
    Hayasaka S; Okabe H; Takahashi J
    Graefes Arch Clin Exp Ophthalmol; 1982; 218(1):9-13. PubMed ID: 7056483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Vogt-Koyanagi-Harada disease-like uveitis during treatment by anti-programmed death-1 antibody: a case report.
    Wang JN; Zhang Y; Huang CY; Li K; Yu XB
    BMC Ophthalmol; 2024 Jun; 24(1):240. PubMed ID: 38849786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease.
    Abu El-Asrar AM; Dosari M; Hemachandran S; Gikandi PW; Al-Muammar A
    Acta Ophthalmol; 2017 Feb; 95(1):85-90. PubMed ID: 27535102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Vogt-Koyanagi-Harada syndrome in children].
    Laghmari M; Karim A; Ibrahimy W; Essakalli NH; Mohcine Z
    J Fr Ophtalmol; 2002 Jun; 25(6):636-40. PubMed ID: 12223954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Vogt-Koyanagi-Harada Disease-like Uveitis during Treatment by Anti-programmed Death Ligand-1 Antibody for Non-small Cell Lung Cancer: A Case Report.
    Suwa S; Tomita R; Kataoka K; Ueno S
    Ocul Immunol Inflamm; 2022 Aug; 30(6):1522-1526. PubMed ID: 33797309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vogt-Koyanagi-Harada syndrome in a 10-year-old child.
    Ghosh AK; Bhaduri G; Deb A; Singh M; Das K
    J Indian Med Assoc; 2007 Apr; 105(4):210, 212. PubMed ID: 17822191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term course of immunosuppressive therapy of Vogt-Koyanagi-Harada syndrome].
    Wand K; Abraham S; Loos D; Stumpfe S; Lohmann C; Maier M; Feucht N
    Ophthalmologe; 2015 Oct; 112(10):857-60. PubMed ID: 25680347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Vogt Koyanagi Harada syndrome in children: diagnosis and management].
    Benfdil N; Baha Ali T; Jellab B; Moutaouakil A
    Bull Soc Belge Ophtalmol; 2010; (314):15-8. PubMed ID: 20480746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vogt-Koyanagi-Harada syndrome.
    Ohno S; Char DH; Kimura SJ; O'Connor GR
    Am J Ophthalmol; 1977 May; 83(5):735-40. PubMed ID: 868972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vogt-Koyanagi-Harada syndrome-like uveitis after nivolumab administration as a treatment for ovarian cancer.
    Hwang GE; Lee JW; Jeon S; Cho IH; Kim HD
    Doc Ophthalmol; 2022 Apr; 144(2):153-162. PubMed ID: 34997406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Adalimumab for Chronic Vogt-Koyanagi-Harada Disease Refractory to Conventional Corticosteroids and Immunosuppressive Therapy and Complicated by Central Serous Chorioretinopathy.
    Takayama K; Obata H; Takeuchi M
    Ocul Immunol Inflamm; 2020 Apr; 28(3):509-512. PubMed ID: 31268769
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-lasting uveitis remission and hearing loss recovery after rituximab in Vogt-Koyanagi-Harada disease.
    Caso F; Rigante D; Vitale A; Costa L; Bascherini V; Latronico E; Franceschini R; Cantarini L
    Clin Rheumatol; 2015 Oct; 34(10):1817-20. PubMed ID: 25224382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclosporin therapy in Vogt Koyanagi Harada disease.
    Wakefield D; McCluskey P; Reece G
    Aust N Z J Ophthalmol; 1990 May; 18(2):137-42. PubMed ID: 2390240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.